The importance of dose intensity in chemotherapy of metastatic breast cancer.
about
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaHigh dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancerWhither high-dose chemotherapy in breast cancer?The Valley of Death in anticancer drug development: a reassessmentGranulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancerAdjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term resultsMitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) supportA feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancerHigh-dose chemotherapy and autologous stem cell transplantation for breast cancer.Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cellsHistorical review of lymphomas.High dose chemotherapy: rationale and results in breast carcinoma.High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials.From circadian rhythms to cancer chronotherapeutics.Dose intensity in cancer chemotherapyPhase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancerRecent advances in the systemic therapy of breast cancer.A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival.Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.Colony-stimulating factors: a new step in clinical practice. Part I.Neutropenia Prediction Based on First-Cycle Blood Counts Using a FOS-3NN Classifier.The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia.Locally advanced breast cancer: report of phase II study and subsequent phase III trialThe use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancerCMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).Weight-based chemotherapy dosing in obese patients with cancer: back to the future.High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma groupHaematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancerHigh-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group.Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy.Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
P2860
Q24240753-AE522836-BF96-45EB-B618-4A4ECCDA6607Q24246595-94DD22A8-3705-43DE-8F23-B26453465F3FQ24801121-3FE11958-C3F0-4D2B-87C9-C58F3E589507Q26861274-10CA0BA5-4920-4649-B3B3-E20B735E7BE6Q28378467-069C7765-1A4B-450B-97DA-D63BD4DF3D5BQ30625567-D601162E-44BC-4615-933F-F07909154EAFQ33334493-650C5D7F-9B7C-4427-A0B1-23C6DD590EFDQ33335297-F4B50794-7B56-4633-ACA7-F18888DE7E88Q33397922-B15F551B-A458-4786-9FBA-237D8B7AE58CQ33488092-D541119B-CDFC-47BD-824D-4B5B08400621Q33488249-190332FC-E11B-4E24-9F0A-888FE2A7D00CQ33495866-038324DC-70C2-4AAA-AA5A-E43FC2BC745EQ33931132-1CFD9D55-432A-41A6-A57B-64D30880C9CBQ33959862-18D2CB6E-4BEB-4C6A-B174-34EDB8173138Q33962044-E82651D7-145E-4B4D-9FCB-FECDF54F289CQ33970577-744A8796-F6C5-4C10-86F4-B5F19001DF0CQ34201582-D9689FCD-3076-400B-985E-7DD603BF2278Q34606456-899A6246-C778-451A-AC65-CB8617C2C011Q34629955-C2C6DDEF-78A1-405C-A193-A4A6F9426BBAQ34743442-59119CB4-C513-47CF-9F93-F3DAE99A29D4Q34779671-CBD37C8F-BFF8-41A5-8692-1A22A6011066Q35052282-5BA14AE8-AA40-4FA5-A0BA-501A159486E7Q35494151-E16036B4-369B-4978-92EA-2BB247EB2B8CQ35536636-C6B59C31-D346-48AB-8AC1-7300FA4E7648Q35659605-B075D2CC-7C3A-4F2D-A0B0-FCD523A41ED8Q35791695-4EED2F37-F76D-4C7D-85BB-4CBDA65319B6Q35992880-F261CE40-B661-44DC-BC17-A5020E347475Q35993092-C147933D-E511-4852-B27E-AEF594A77691Q36080547-A14F6021-C070-412F-AA49-A59EA09464DAQ36081039-9EE1DF86-55C0-44FA-9BB8-6C0CB0C5E812Q36095287-8C603C83-7A68-4E42-91AD-B02EDBB9E5D9Q36114975-D93BB33A-7CA6-4CA3-BE58-3445573E60ACQ36115868-AA26A447-F44C-4448-BAEE-623505F8926AQ36115998-F6C9EAA4-C6FD-4C33-880C-24E698E1F1A5Q36136361-DD5868F9-48CC-48FD-BAA7-2B0D221A9940Q36136402-C244B925-0F60-44EF-AEBF-DA2D97C6BFE7Q36140983-00547FDD-8E38-4315-A1A1-F77248F2135CQ36467090-0C0C2A47-3822-4EFD-9DCE-BF157643A8BAQ36467596-BEAFB407-3060-41BB-B97C-F1CCE49E1EE6Q36619863-834B454A-90C5-45BF-91A7-10CBD6C70960
P2860
The importance of dose intensity in chemotherapy of metastatic breast cancer.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
The importance of dose intensity in chemotherapy of metastatic breast cancer.
@en
type
label
The importance of dose intensity in chemotherapy of metastatic breast cancer.
@en
prefLabel
The importance of dose intensity in chemotherapy of metastatic breast cancer.
@en
P1476
The importance of dose intensity in chemotherapy of metastatic breast cancer.
@en
P2093
P304
P356
10.1200/JCO.1984.2.11.1281
P407
P577
1984-11-01T00:00:00Z